Oncology Central

“These long-term data results are off the chart and this study confirms the outstanding durable efficacy of lorlatinib as a first-line choice for patients with ALK-positive NSCLC.” Benjamin Soloman (Peter MacCallum Cancer Center, Australia) Find out about the groundbreaking CROWN study and more in our Top 10 article countdown of 2024 >>> https://hubs.ly/Q0300py80

Researchers from King's College London have developed new approaches for identifying treatment-resistant NSCLC before treatment initiation, allowing for better treatment staging. “With this technique, we can give the right treatment to the right patient, making it more cost-efficient for the NHS and providing hope for patients with aggressive tumors” ―Tim Whitney (Kings College London) Read more about their work >>> https://bit.ly/4gVcIeg

As we approach 2025, we are taking the opportunity to reflect on the standout moments of this year. Discover breaking news from ESMO 2024 and ASCO 2024, how researchers are tackling cancer inequalities as well as latest breakthroughs in immuno-oncology. Find out more in our Top 10 articles of 2024 >>> https://hubs.ly/Q0300hGp0

Acute myeloid leukemia's aggressive progression means prompt intervention is essential. This White Paper emphasizes the critical role of genetic testing in guiding therapeutic decisions, highlighting the potential of the AML Express Assay >>> https://hubs.ly/Q02ZkJ5z0 This content was provided by NeoGenomics Laboratories

Curious about the latest breakthroughs in #KRAS #LungCancer treatment? Check out this webinar from KRAS Kickers 📅 Dec 17, 2024 | ⏰ 1 PM ET 👥 Featuring Dr. Colin Lindsay & Terri Conneran Topics: ✅ KRAS lung cancer treatments ✅ Clinical trials + research updates Register now: https://hubs.ly/Q02_L1f_0

Acute myeloid leukemia is expected to affect over 20,000 this year in the US alone, underscoring the importance of early and accurate diagnostics in hematology. This White Paper identifies an unmet need for rapid diagnostics and personalized treatment options whilst presenting an express solution >>> https://hubs.ly/Q02ZkKhT0 This content was provided by NeoGenomics Laboratories #AML #NGS

This week in the Oncology Central newsletter, we’re bringing you key headlines from the SABCS conference in one convenient place, amongst the many headlines is, 'Should tamoxifen be considered for DCIS patients after breast conserving surgery?' #OncologyCentralNewsletter

Treating rare cancers like soft tissue sarcoma remains complex. Findings from the SU2C-SARC032 trial suggest that pembrolizumab combined with radiation therapy could improve outcomes for specific #sarcoma subtypes. Find out more >>> https://hubs.ly/Q02-kBnC0

The results of a combined dataset of two clinical trials, presented at #SABCS2024 revealed that tamoxifen may reduce the risk of recurrence in “good-risk” DCIS patients who do not receive radiotherapy. Find out more >>> https://hubs.ly/Q02_tTZg0

A brain-penetrating SERD termed imlunestrant is effective in treating ESR1-mutated breast cancer, either as a monotherapy or in combination with a CDK4/6 inhibitor. #SABCS24 https://hubs.ly/Q02_tZvH0